Literature DB >> 6350189

Possible role of enteric organisms in the pathogenesis of ankylosing spondylitis and other seronegative arthropathies.

J K Prendergast, J S Sullivan, A Geczy, L I Upfold, J P Edmonds, H V Bashir, E Reiss-Levy.   

Abstract

One-hundred eighty-five clinical isolates of Salmonella sp., Shigella sp., Escherichia coli, and Campylobacter sp. were tested for their ability to absorb the lymphocytotoxic activity of an antiserum (anti-Klebsiella sp. K43) directed against a specific HLA-B27-associated cell surface determinant on the lymphocytes of patients with ankylosing spondylitis (AS). Seven of these isolates (three Salmonella sp., two Shigella sp., one E. coli, and one Campylobacter sp.) were found to cross-react with the B27-positive cells of AS patients (B27+ AS+); an E. coli organism isolated from the rectal swab of an HLA-B27-negative clinically normal individual also cross-reacted with B27+ AS+ cells. These cross-reactive enteric organisms elaborate a factor (modifying factor) which specifically modifies the B27-positive lymphocytes of normal individuals; this factor is structurally and antigenically related to a functionally similar factor secreted by certain isolates of Klebsiella sp. These data suggest that certain enteric organisms share a common determinant which cross-reacts with B27+ AS+ cells. It is suggested that this cross-reactivity is somehow related to an early event in the pathogenesis of AS and possibly of other seronegative arthropathies.

Entities:  

Mesh:

Year:  1983        PMID: 6350189      PMCID: PMC264591          DOI: 10.1128/iai.41.3.935-941.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Production and in vivo effect of antibodies against guinea pig lymphokines.

Authors:  C L Geczy; W Friedrich; A L de Weck
Journal:  Cell Immunol       Date:  1975-09       Impact factor: 4.868

2.  Klebsiella pneumoniae and acute anterior uveitis in ankylosing spondylitis.

Authors:  R Ebringer; D Cawdell; A Ebringer
Journal:  Br Med J       Date:  1979-02-10

3.  Adherence of Escherichia coli to human mucosal cells mediated by mannose receptors.

Authors:  I Ofek; D Mirelman; N Sharon
Journal:  Nature       Date:  1977-02-17       Impact factor: 49.962

4.  HL-A 27 in reactive arthritis. A study of Yersinia arthritis and Reiter's disease.

Authors:  K Aho; P Ahvonen; A Lassus; K Sievers; A Tiilikainen
Journal:  Arthritis Rheum       Date:  1974 Sep-Oct

5.  Letter: Salmonella arthritis and HL-A27.

Authors:  J Friis; A Svejgaard
Journal:  Lancet       Date:  1974-06-29       Impact factor: 79.321

6.  Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test.

Authors:  K K Mittal; M R Mickey; D P Singal; P I Terasaki
Journal:  Transplantation       Date:  1968-11       Impact factor: 4.939

7.  HLA-B27, Klebsiella, and ankylosing spondylitis.

Authors:  A F Geczy; J Yap
Journal:  Lancet       Date:  1979-03-31       Impact factor: 79.321

8.  A factor(s) in Klebsiella culture filtrates specifically modifies an HLA-B27 associated cell-surface component.

Authors:  A F Geczy; K Alexander; H V Bashir; J Edmonds
Journal:  Nature       Date:  1980-02-21       Impact factor: 49.962

9.  An "experimental" epidemic of Reiter's syndrome.

Authors:  H R Noer
Journal:  JAMA       Date:  1966-11-14       Impact factor: 56.272

10.  Sequential studies in ankylosing spondylitis. Association of Klebsiella pneumoniae with active disease.

Authors:  R W Ebringer; D R Cawdell; P Cowling; A Ebringer
Journal:  Ann Rheum Dis       Date:  1978-04       Impact factor: 19.103

View more
  16 in total

1.  Polyclonal B cell activation in ankylosing spondylitis.

Authors:  P Barbieri; I Olivieri; G Benedettini; P Marelli; M L Ciompi; G Pasero; M Campa
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

2.  Possible role of HLA-B27 associated cytotoxic T lymphocyte activity in the pathogenesis of the seronegative arthropathies.

Authors:  A F Geczy; J S Sullivan
Journal:  Ann Rheum Dis       Date:  1995-05       Impact factor: 19.103

Review 3.  Intestinal permeability, non-steroidal anti-inflammatory drug enteropathy and inflammatory bowel disease: an overview.

Authors:  I Bjarnason; T J Peters
Journal:  Gut       Date:  1989-11       Impact factor: 23.059

4.  HLA-B27 associated cross-reactive marker on the cells of New Zealand patients with ankylosing spondylitis.

Authors:  L E McGuigan; A F Geczy; J K Prendergast; J P Edmonds; H H Hart; H V Bashir
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

5.  Ankylosing spondylitis, HLA-B27, and klebsiella.

Authors:  A F Geczy
Journal:  Ann Rheum Dis       Date:  1986-03       Impact factor: 19.103

6.  Proceedings of Irish Association for Rheumatology and Rehabilitation and Society of Irish and American Rheumatologists: combined meeting. October 11, 1985. Abstracts.

Authors: 
Journal:  Ir J Med Sci       Date:  1986-12       Impact factor: 1.568

7.  HLA-B27, molecular mimicry, and ankylosing spondylitis: popular misconceptions.

Authors:  A F Geczy; J K Prendergast; J S Sullivan; L I Upfold; L E McGuigan; H V Bashir; M Prendergast; J P Edmonds
Journal:  Ann Rheum Dis       Date:  1987-02       Impact factor: 19.103

8.  Rabbit antisera to cross-reactive organisms--where's the problem.

Authors:  A F Geczy; L I Upfold; J S Sullivan; J K Prendergast; L E McGuigan; H V Bashir; J P Edmonds
Journal:  Ann Rheum Dis       Date:  1986-01       Impact factor: 19.103

9.  Significance of non-pathogenic cross reactive bowel flora in patients with ankylosing spondylitis.

Authors:  L E McGuigan; J K Prendergast; A F Geczy; J P Edmonds; H V Bashir
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

10.  Raised circulating levels of the eosinophil cationic protein in ankylosing spondylitis: relation with the inflammatory activity and the influence of sulphasalazine treatment.

Authors:  N Feltelius; R Hällgren; P Venge
Journal:  Ann Rheum Dis       Date:  1987-05       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.